Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

2008 • 25,031 citations

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

2010 • 14,016 citations

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

2015 • 8,603 citations

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

2015 • 7,844 citations

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

2015 • 7,407 citations

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

2011 • 4,304 citations

Nivolumab plus Ipilimumab in Advanced Melanoma

2013 • 4,054 citations

Optimal two-stage designs for phase II clinical trials

1989 • 3,494 citations

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

2015 • 2,612 citations

CTLA-4 and PD-1 Pathways

2015 • 1,869 citations

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

2010 • 1,711 citations

Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

2010 • 1,091 citations

Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer

2006 • 654 citations

Small cell lung cancer: Where do we go from here?

2014 • 561 citations

Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer

2014 • 306 citations

Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma

2014 • 277 citations

Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non–Small Cell Lung Cancer

2015 • 181 citations

Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy

2016 • 172 citations

Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker

2012 • 171 citations

A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease

2010 • 141 citations

Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma

2015 • 134 citations

Posterior Reversible Encephalopathy Syndrome During Ipilimumab Therapy for Malignant Melanoma

2011 • 123 citations

A German multicenter, randomized phase III trial comparing irinotecan–carboplatin with etoposide–carboplatin as first-line therapy for extensive-disease small-cell lung cancer

2011 • 109 citations

Treatment options for small cell lung cancer – do we have more choice?

2010 • 109 citations

Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma

2014 • 107 citations

Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028.

2015 • 86 citations

Relapsed small cell lung cancer: treatment options and latest developments

2014 • 80 citations

Expanded cohort results from CheckMate 016: A phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).

2015 • 67 citations

Histologic Assessment of Tumor-Associated CD45+ Cell Numbers Is an Independent Predictor of Prognosis in Small Cell Lung Cancer

2013 • 61 citations

Nivolumab dose selection: challenges, opportunities and lessons learned for cancer immunotherapy

2015 • 22 citations

Ipilimumab Induced Encephalitis: A Case Report

2015 • 15 citations